|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIFC1 |
Gene summary for KIFC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIFC1 | Gene ID | 3833 |
| Gene name | kinesin family member C1 | |
| Gene Alias | HSET | |
| Cytomap | 6p21.32 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RCS7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3833 | KIFC1 | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 2.91e-01 | 0.0655 |
| 3833 | KIFC1 | P1T-E | Human | Esophagus | ESCC | 2.97e-02 | 2.69e-01 | 0.0875 |
| 3833 | KIFC1 | P2T-E | Human | Esophagus | ESCC | 6.44e-09 | 5.86e-01 | 0.1177 |
| 3833 | KIFC1 | P4T-E | Human | Esophagus | ESCC | 1.78e-10 | 3.20e-01 | 0.1323 |
| 3833 | KIFC1 | P5T-E | Human | Esophagus | ESCC | 1.76e-12 | 2.97e-01 | 0.1327 |
| 3833 | KIFC1 | P9T-E | Human | Esophagus | ESCC | 5.23e-05 | 1.74e-01 | 0.1131 |
| 3833 | KIFC1 | P10T-E | Human | Esophagus | ESCC | 1.00e-04 | 2.29e-01 | 0.116 |
| 3833 | KIFC1 | P15T-E | Human | Esophagus | ESCC | 8.45e-04 | 1.44e-01 | 0.1149 |
| 3833 | KIFC1 | P16T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.52e-01 | 0.1153 |
| 3833 | KIFC1 | P17T-E | Human | Esophagus | ESCC | 9.15e-12 | 6.37e-01 | 0.1278 |
| 3833 | KIFC1 | P20T-E | Human | Esophagus | ESCC | 2.18e-03 | 1.45e-01 | 0.1124 |
| 3833 | KIFC1 | P21T-E | Human | Esophagus | ESCC | 2.05e-07 | 2.80e-01 | 0.1617 |
| 3833 | KIFC1 | P23T-E | Human | Esophagus | ESCC | 9.87e-03 | 1.63e-01 | 0.108 |
| 3833 | KIFC1 | P24T-E | Human | Esophagus | ESCC | 6.56e-15 | 4.97e-01 | 0.1287 |
| 3833 | KIFC1 | P26T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.34e-01 | 0.1276 |
| 3833 | KIFC1 | P27T-E | Human | Esophagus | ESCC | 4.17e-05 | 2.02e-01 | 0.1055 |
| 3833 | KIFC1 | P28T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.34e-01 | 0.1149 |
| 3833 | KIFC1 | P30T-E | Human | Esophagus | ESCC | 7.79e-07 | 4.30e-01 | 0.137 |
| 3833 | KIFC1 | P31T-E | Human | Esophagus | ESCC | 1.97e-10 | 3.17e-01 | 0.1251 |
| 3833 | KIFC1 | P32T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.54e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:005131011 | Esophagus | ESCC | metaphase plate congression | 58/8552 | 65/18723 | 1.81e-13 | 8.63e-12 | 58 |
| GO:000708011 | Esophagus | ESCC | mitotic metaphase plate congression | 47/8552 | 50/18723 | 3.15e-13 | 1.47e-11 | 47 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:005130311 | Esophagus | ESCC | establishment of chromosome localization | 67/8552 | 80/18723 | 1.92e-12 | 8.09e-11 | 67 |
| GO:005000011 | Esophagus | ESCC | chromosome localization | 68/8552 | 82/18723 | 3.37e-12 | 1.32e-10 | 68 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:00512256 | Esophagus | ESCC | spindle assembly | 85/8552 | 117/18723 | 2.72e-09 | 5.98e-08 | 85 |
| GO:009030715 | Esophagus | ESCC | mitotic spindle assembly | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:01400145 | Oral cavity | OSCC | mitotic nuclear division | 191/7305 | 287/18723 | 1.99e-21 | 3.70e-19 | 191 |
| GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
| GO:00000702 | Oral cavity | OSCC | mitotic sister chromatid segregation | 118/7305 | 168/18723 | 1.89e-16 | 1.48e-14 | 118 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIFC1 | SNV | Missense_Mutation | rs533235601 | c.956C>T | p.Pro319Leu | p.P319L | Q9BW19 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| KIFC1 | SNV | Missense_Mutation | c.95G>T | p.Gly32Val | p.G32V | Q9BW19 | protein_coding | deleterious(0.01) | benign(0.274) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| KIFC1 | SNV | Missense_Mutation | c.253N>G | p.Gln85Glu | p.Q85E | Q9BW19 | protein_coding | tolerated(0.73) | benign(0.015) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| KIFC1 | SNV | Missense_Mutation | rs769727957 | c.1066N>T | p.Arg356Trp | p.R356W | Q9BW19 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| KIFC1 | SNV | Missense_Mutation | c.1964N>A | p.Arg655His | p.R655H | Q9BW19 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| KIFC1 | SNV | Missense_Mutation | c.955N>T | p.Pro319Ser | p.P319S | Q9BW19 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| KIFC1 | SNV | Missense_Mutation | c.458N>T | p.Cys153Phe | p.C153F | Q9BW19 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-E2-A14Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| KIFC1 | SNV | Missense_Mutation | c.1973C>T | p.Ser658Phe | p.S658F | Q9BW19 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E2-A15R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| KIFC1 | insertion | In_Frame_Ins | novel | c.1252_1253insATGGTGAAACCCCGTCTTTAC | p.Phe418delinsTyrGlyGluThrProSerLeuLeu | p.F418delinsYGETPSLL | Q9BW19 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| KIFC1 | SNV | Missense_Mutation | c.380N>A | p.Gly127Glu | p.G127E | Q9BW19 | protein_coding | tolerated(0.09) | benign(0.118) | TCGA-C5-A1ML-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |